Bank of America Corp DE Has $9.85 Million Stake in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Bank of America increased its Collegium Pharmaceutical stake by 52.5% in the first quarter, owning 297,847 shares valued at approximately $9.85 million, or 0.92% of the company.
• Analysts maintain a “Moderate Buy” consensus with a $51 average price target, although several firms recently lowered their targets or downgraded the stock to “Hold.”
• Collegium reported quarterly EPS of $1.92, exceeding estimates of $1.72, while revenue rose 6.3% year over year to $199.88 million; shares opened at $27.11, near their 52-week low.

Bank of America Corp DE lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,847 shares of the specialty pharmaceutical company's stock after purchasing an additional 102,502 shares during the quarter. Bank of America Corp DE owned 0.92% of Collegium Pharmaceutical worth $9,850,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company's stock valued at $93,374,000 after purchasing an additional 157,743 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company's stock worth $104,465,000 after buying an additional 29,876 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock worth $60,358,000 after buying an additional 377,073 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company's stock worth $74,883,000 after buying an additional 18,160 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company's stock valued at $60,823,000 after buying an additional 3,891 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on COLL. Zacks Research cut Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Needham & Company LLC lowered their price objective on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

Collegium Pharmaceutical Price Performance

COLL stock opened at $27.11 on Monday. Collegium Pharmaceutical, Inc. has a 1-year low of $25.47 and a 1-year high of $50.79. The business's 50 day simple moving average is $33.67 and its 200 day simple moving average is $35.70. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $882.59 million, a PE ratio of 21.86 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same period in the prior year, the firm earned $1.68 earnings per share. The company's revenue was up 6.3% on a year-over-year basis. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source